• Je něco špatně v tomto záznamu ?

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease

V. Tesar, K. Ciechanowski, Y. Pei, I. Barash, M. Shannon, R. Li, JH. Williams, M. Levisetti, S. Arkin, A. Serra,

. 2017 ; 28 (11) : 3404-3413. [pub] 20170824

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016392
E-zdroje Online Plný text

NLK Free Medical Journals od 1990 do Před 1 rokem
PubMed Central od 2008 do Před 1 rokem
Europe PubMed Central od 2008 do Před 1 rokem
Open Access Digital Library od 1990-07-01

Odkazy

PubMed 28838955
DOI 10.1681/asn.2016111232
Knihovny.cz E-zdroje

Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients with ADPKD, eGFR≥60 ml/min per 1.73 m2, and total kidney volume ≥750 ml were randomized 1:1:1 to bosutinib 200 mg/d, bosutinib 400 mg/d, or placebo for ≤24 months. The primary endpoint was annualized rate of kidney enlargement in patients treated for ≥2 weeks who had at least one postbaseline magnetic resonance imaging scan that was preceded by a 30-day washout (modified intent-to-treat population). Of 172 enrolled patients, 169 received at least one study dose. Per protocol amendment, doses for 24 patients who initially received bosutinib at 400 mg/d were later reduced to 200 mg/d. The annual rate of kidney enlargement was reduced by 66% for bosutinib 200 mg/d versus placebo (1.63% versus 4.74%, respectively; P=0.01) and by 82% for pooled bosutinib versus placebo (0.84% versus 4.74%, respectively; P<0.001). Over the treatment period, patients receiving placebo or bosutinib had similar annualized eGFR decline. Gastrointestinal and liver-related adverse events were the most frequent toxicities. In conclusion, compared with placebo, bosutinib at 200 mg/d reduced kidney growth in patients with ADPKD. The overall gastrointestinal and liver toxicity profile was consistent with the profile in prior studies of bosutinib; no new toxicities were identified. (ClinicalTrials.gov: NCT01233869).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016392
003      
CZ-PrNML
005      
20180518092834.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1681/ASN.2016111232 $2 doi
035    __
$a (PubMed)28838955
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tesar, Vladimir $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Vladimir.Tesar@vfn.cz.
245    10
$a Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease / $c V. Tesar, K. Ciechanowski, Y. Pei, I. Barash, M. Shannon, R. Li, JH. Williams, M. Levisetti, S. Arkin, A. Serra,
520    9_
$a Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients with ADPKD, eGFR≥60 ml/min per 1.73 m2, and total kidney volume ≥750 ml were randomized 1:1:1 to bosutinib 200 mg/d, bosutinib 400 mg/d, or placebo for ≤24 months. The primary endpoint was annualized rate of kidney enlargement in patients treated for ≥2 weeks who had at least one postbaseline magnetic resonance imaging scan that was preceded by a 30-day washout (modified intent-to-treat population). Of 172 enrolled patients, 169 received at least one study dose. Per protocol amendment, doses for 24 patients who initially received bosutinib at 400 mg/d were later reduced to 200 mg/d. The annual rate of kidney enlargement was reduced by 66% for bosutinib 200 mg/d versus placebo (1.63% versus 4.74%, respectively; P=0.01) and by 82% for pooled bosutinib versus placebo (0.84% versus 4.74%, respectively; P<0.001). Over the treatment period, patients receiving placebo or bosutinib had similar annualized eGFR decline. Gastrointestinal and liver-related adverse events were the most frequent toxicities. In conclusion, compared with placebo, bosutinib at 200 mg/d reduced kidney growth in patients with ADPKD. The overall gastrointestinal and liver toxicity profile was consistent with the profile in prior studies of bosutinib; no new toxicities were identified. (ClinicalTrials.gov: NCT01233869).
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a aniliny $x škodlivé účinky $x terapeutické užití $7 D000814
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nitrily $x škodlivé účinky $x terapeutické užití $7 D009570
650    _2
$a polycystické ledviny autozomálně dominantní $x farmakoterapie $7 D016891
650    _2
$a chinoliny $x škodlivé účinky $x terapeutické užití $7 D011804
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Ciechanowski, Kazimierz $u Department of Nephrology, Pomeranian Medical University, Szczecin, Poland.
700    1_
$a Pei, York $u Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
700    1_
$a Barash, Irina $u Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York.
700    1_
$a Shannon, Megan $u Worldwide Research and Development, Pfizer Inc, San Diego, California.
700    1_
$a Li, Ray $u Early Oncology Development and Clinical Research and.
700    1_
$a Williams, Jason H $u Worldwide Research and Development, Pfizer Inc, San Diego, California.
700    1_
$a Levisetti, Matteo $u Worldwide Research and Development, Pfizer Inc, San Diego, California.
700    1_
$a Arkin, Steven $u Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts; and.
700    1_
$a Serra, Andreas $u Suisse ADPKD, Institute of Internal Medicine and Nephrology, Klinik Hirslanden, Zürich, Switzerland.
773    0_
$w MED00002977 $t Journal of the American Society of Nephrology JASN $x 1533-3450 $g Roč. 28, č. 11 (2017), s. 3404-3413
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28838955 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180518093012 $b ABA008
999    __
$a ok $b bmc $g 1300016 $s 1013232
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 28 $c 11 $d 3404-3413 $e 20170824 $i 1533-3450 $m Journal of the American Society of Nephrology $n J Am Soc Nephrol $x MED00002977
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace